Assignee: Inspire Pharmaceuticals, Inc.

Location: Durham, NC
No. of patents: 82

Number	Title	Issue Date
7947850	Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones The present invention is directed to practical high-yielding synthetic processes for preparing 3,4-disubstituted-thiazolidin-2-ones, which do not compromise the absolute stereochemical integrity of the compounds. The present invention is also directed to novel compo...	05/24/2011
7943760	Non-nucleotide composition for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharm...	05/17/2011
7939510	Di(uridine 5′-)tetraphosphate and salts thereof The present invention are directed to P1,P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1...	05/10/2011
7932376	Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharm...	04/26/2011
7851456	P2Y6 receptor agonists for treating lung diseases This invention is directed to a method of enhancing or facilitating the clearance of the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is furthe...	12/14/2010
7785624	Pharmaceutical latrunculin formulations The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceuti...	08/31/2010
7759322	Method of treating dry eye disease with purinergic receptor agonists A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucl...	07/20/2010
7749981	Drug-eluting stents coated with non-nucleotide P2Yreceptor antagonist compound The present invention provides a drug-eluting stent, wherein the stent is coated with one or more non-nucleotide P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed...	07/06/2010
7749980	Non-nucleotide compositions and method for treating pain The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain...	07/06/2010
7741473	Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles The present invention is directed to a processes for the synthesis of trans isomer of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles (Formula I). The process comprises the steps of: (a) obtaining a compound of Formula II, which ...	06/22/2010
7666861	Cytoskeletal active compounds, composition and use The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable...	02/23/2010
7618949	Drug-eluting stents coated with P2Yreceptor antagonist compound The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the ste...	11/17/2009
7612047	Degradation-resistant mononucleoside phosphate compounds The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on ...	11/03/2009
7592445	Non-nucleotide composition and method for inhibiting platelet aggregation This invention is directed to compounds of Formulae III and V, useful for treating diseases or conditions associated with platelet aggregation. ...	09/22/2009
7531525	P-(2′-deoxycytidine 5′-)P-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from...	05/12/2009
7528119	Di(uridine 5′-)tetraphosphate and salts thereof The present invention are directed to P1,P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1...	05/05/2009
7504497	Orally bioavailable compounds and methods for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharm...	03/17/2009
7452870	Drug-eluting stents coated with P2Yreceptor antagonist compound The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the ste...	11/18/2008
7435724	Degradation-resistant mononucleoside phosphate compounds The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on ...	10/14/2008
7432252	Method of promoting cervical and vaginal secretions The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2 and/or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and variou...	10/07/2008
7414137	Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones The present invention is directed to practical high-yielding synthetic processes for preparing 3,4-disubstituted-thiazolidin-2-ones, which do not compromise the absolute stereochemical integrity of the compounds. The present invention is also directed to novel compo...	08/19/2008
7378082	Method for treating allergic rhinitis without adverse effects The present invention is directed to a method for treating allergic rhinitis without causing an adverse effect of bitter taste. The method comprises administering to a patient an aqueous pharmaceutical formulation comprising 0.1-0.15% (w/v) of epinastine or an acid ...	05/27/2008
7368438	Non-nucleotide compositions and method for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharm...	05/06/2008
7335648	Non-nucleotide composition and method for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a compounds usefu...	02/26/2008
7320974	Cytoskeletal active compounds, compositions and use The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable...	01/22/2008
7256183	Method for treating or preventing inflammatory diseases The present invention provides a method of preventing or treating an inflammatory disease, including but not limited to, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory bowel disease, inflammatory collagen vascular diseases, glomerulonephritis,...	08/14/2007
7247623	Method of treating dry eye disease with non-drying antihistamines A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the eyes of the subject a non-drying antihistamine compound, such as epinastine hydrochlori...	07/24/2007
7235535	Method of enhancing drainage of lacrimal system with purinergic receptor agonists A method and preparation for enhancing drainage of lacrimal system in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), di...	06/26/2007
7223744	Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from...	05/29/2007
7132408	Composition and method for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition...	11/07/2006
7132410	Di(uridine 5′-)tetraphosphate and salts thereof The present invention are directed to P1, P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1	11/07/2006
7115585	Compositions for treating epithelial and retinal tissue diseases The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation resistant substituent on ...	10/03/2006
7109181	Joint lubrication with P2Y purinergic receptor agonists The present invention is directed to a method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment. The method comprises administering to a subject a pharmaceutical composition comprising a P2Y purinerg...	09/19/2006
7101860	Composition and method for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition...	09/05/2006
7091334	Method for large-scale production of di(uridine 5′)-tetraphosphate and salts thereof The present invention provides new methods for the synthesis of the therapeutic dinucleotide, P1,P4-di(uridine 5′)-tetraphosphate, and demonstrates applicability to the production of large quantities. The methods of the present invention subs...	08/15/2006
7084128	Method for reducing intraocular pressure The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a purinerginic receptor ligand, which is a mononucleoside polyphosphate or ...	08/01/2006
7078391	Method of treating edematous retinal disorders The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from...	07/18/2006
7018985	Composition and method for inhibiting platelet aggregation The present invention provides novel compounds of dinucleotide polyphosphates and the method of preventing or treating diseases or conditions associated with platelet aggregation. The method comprises administering systemically to a patient a pharmaceutical comprisi...	03/28/2006
6984629	Ectocornea extension promoters Based on research for compounds that can display a corneal epithelial migration promoting effect in ophthalmology, the present invention provides P2Y receptor agonist corneal epithelial migration promoters, such as phosphoric acid compounds having an adenosyl group,...	01/10/2006
6977246	Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency The present invention relates to certain novel dinucleotides and formulations thereof which are highly selective agonists of the P2Y2 and/or P2Y4 purinergic receptor. They are useful in the treatment of chronic obstructive pulmonary diseases su...	12/20/2005

«First «Previous1 2 3 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: Inspire Pharmaceuticals, Inc.